Pharmaceutical

New Ebola Outbreak Detected in Western Congo

By CMISep 15, 20202 min read
New Ebola Outbreak Detected in Western Congo

The symptoms of the Ebola virus include lack of appetite, weakness, sore throat, abdominal pain, muscle and joint pain, headache, and fever.

On 1 June, the Government of the Democratic Republic of the Congo declared that a new outbreak of Ebola virus disease (EVD) is spreading in Wangata Health Zone, near Mbandaka, in Équateur province of DRC. The government has reported six cases since May 18, including four deaths. Three out of six cases have been laboratory confirmed, and for secondary confirmation, the samples are being sent to Kinshasa. The announcement comes as a complex and difficult Ebola outbreak in the Eastern DRC.

The country also suffers from the novel coronavirus (COVID-19 pandemic) and the world's major measles outbreak. Out of six two are alive and under care, and four have died. It is expected that more individuals will be identified with the EVD as surveillance activities increase. The disease is back in the spotlight as being detected in the northwest DRC. Currently, the world is facing health emergency amid the global pandemic (COVID-19) which has infected more than 6.26 million individuals around the world and has killed more than 375,513 people across the globe. However, the World Health Organization (WHO) has also confirmed that the new outbreak in Wangata Health Zone, DRC.

In 1976, the Ebola virus was first discovered in the DRC and since then it is the 11th Ebola outbreak in the country. Scientists do not know where the Ebola virus comes from. However, they believe the Ebola virus came from the animal. The most expected sources are non-human primates or bats, as per the Centers for Disease Control and Prevention (CDC). The symptoms of the Ebola virus include lack of appetite, weakness, sore throat, abdominal pain, muscle and joint pain, headache, and fever. On December 19, 2019, the United States Food and Drug Administration (FDA) has approved the Ebola vaccine named rVSV-ZEBOV.

Share this story

About Author

Nayan Ingle

is an Associate Content Writer with 3.5 years of experience specializing in research, content writing, SEO optimization, and market analysis, primarily within the consumer goods, packaging, semiconductor, and aerospace & defense domains. He has a proven track record of crafting insightful and engaging content that enhances digital visibility and provides valuable industry perspectives. Nayan’s expertise lies in producing content that is not only informative but also strategically optimized to reach target audiences effectively. His ability to blend market analysis with SEO strategies ensures that his work is both relevant and highly discoverable.

With an MBA in Systems (IT), Nayan brings a strong foundation in market strategies, business analytics, and research methodologies to his writing. This unique blend of skills allows him to offer in-depth analysis and thought leadership across a variety of content formats, including blogs, news articles, and editorial pieces. Passionate about delivering quality, Nayan is dedicated to providing readers with content that not only informs but also adds depth to ongoing industry conversations. His work reflects a commitment to excellence, and he continues to refine his approach as he keeps pace with evolving market trends.